

Linus Jnsson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/359652/linus-jonsson-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92
papers

8,314
citations

39
h-index

91
g-index

117
ext. papers

9,486
ext. citations

3.3
avg, IF

5.78
L-index

#	Paper	IF	Citations
92	Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. <i>Neurology</i> , 2021 , 96, e2220-e2230	6.5	22
91	Predicting time to relapse in patients with schizophrenia according to patientsTrelapse history: a historical cohort study using real-world data in Sweden.. <i>BMC Psychiatry</i> , 2021 , 21, 634	4.2	1
90	The art of simulation. <i>The Lancet Healthy Longevity</i> , 2020 , 1, e2-e3	9.5	1
89	Dynamic Electronic hEalth reCord deTectioN (DETECT) of individuals at risk of a first episode of psychosis: a case-control development and validation study. <i>The Lancet Digital Health</i> , 2020 , 2, e229-e239	14.4	17
88	Controlling for selective dropout in longitudinal dementia data: Application to the SveDem registry. <i>Alzheimer's and Dementia</i> , 2020 , 16, 789-796	1.2	6
87	Costs of Inpatient Rehabilitation for Ischemic Stroke in Patients with Dementia: A Cohort Swedish Register-Based Study. <i>Journal of Alzheimer's Disease</i> , 2020 , 73, 967-979	4.3	3
86	Transdiagnostic individualized clinically-based risk calculator for the automatic detection of individuals at-risk and the prediction of psychosis: external replication in 2,430,333 US patients. <i>Translational Psychiatry</i> , 2020 , 10, 364	8.6	7
85	Real-Life Outcome in Multiple Sclerosis in the Czech Republic. <i>Multiple Sclerosis International</i> , 2019 , 2019, 7290285	1.1	4
84	Identifying and characterizing treatment-resistant schizophrenia in observational database studies. <i>International Journal of Methods in Psychiatric Research</i> , 2019 , 28, e1778	4.3	5
83	Assessing cost-effectiveness of early intervention in Alzheimer's disease: An open-source modeling framework. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1309-1321	1.2	19
82	The effect of self-assessed fatigue and subjective cognitive impairment on work capacity: The case of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 740-749	5	26
81	Effects of an Empowerment-Based Health-Promotion School Intervention on Physical Activity and Sedentary Time among Adolescents in a Multicultural Area. <i>International Journal of Environmental Research and Public Health</i> , 2018 , 15,	4.6	5
80	Inventory of real world data sources in Parkinson's disease. <i>BMC Neurology</i> , 2017 , 17, 213	3.1	3
79	The worldwide costs of dementia 2015 and comparisons with 2010. <i>Alzheimer's and Dementia</i> , 2017 , 13, 1-7	1.2	547
78	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology</i> , 2016 , 15, 455-532	24.1	921
77	Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherapy. The SARcoma treatment and Burden of Illness in North America and Europe (SABINE) study. <i>European Journal of Cancer Care</i> , 2016 , 25, 466-77	2.4	4
76	The societal costs of dementia in Sweden 2012 - relevance and methodological challenges in valuing informal care. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 59	9	20

75	Health-related quality of life among children, young people and adults with esophageal atresia: a review of the literature and recommendations for future research. <i>Quality of Life Research</i> , 2015 , 24, 2433-45	3.7	27
74	Physiological Studies at 7 Years of Age in Children Born with Esophageal Atresia. <i>European Journal of Pediatric Surgery</i> , 2015 , 25, 397-404	1.9	11
73	Individual experiences following a 6-month exercise intervention: A qualitative study. <i>International Journal of Qualitative Studies on Health and Well-being</i> , 2015 , 10, 26376	2	10
72	Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation. <i>Value in Health</i> , 2014 , 17, 707-13	3.3	39
71	Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria. <i>Journal of Internal Medicine</i> , 2014 , 275, 304-16	10.8	43
70	Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study. <i>Cancer Management and Research</i> , 2014 , 6, 365-71	3.6	2
69	Early regenerative response in the intrathoracic porcine esophagus-the impact of the inflammation. <i>Artificial Organs</i> , 2014 , 38, 439-46	2.6	8
68	Costs explained by function rather than diagnosis--results from the SNAC Nordanstig elderly cohort in Sweden. <i>International Journal of Geriatric Psychiatry</i> , 2013 , 28, 454-62	3.9	21
67	The worldwide economic impact of dementia 2010. <i>Alzheimer's and Dementia</i> , 2013 , 9, 1-11.e3	1.2	641
66	Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece. <i>BMC Health Services Research</i> , 2013 , 13, 173	2.9	10
65	SCOPE: a scorecard for osteoporosis in Europe. <i>Archives of Osteoporosis</i> , 2013 , 8, 144	2.9	99
64	Application of Resource Utilization in Dementia (RUD) instrument in a global setting. <i>Alzheimer's and Dementia</i> , 2013 , 9, 429-435.e17	1.2	93
63	Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports. <i>Lupus</i> , 2013 , 22, 793-801	2.6	34
62	Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort. <i>European Journal of Health Economics</i> , 2012 , 13, 561-8	3.6	4
61	The economic cost of brain disorders in Europe. <i>European Journal of Neurology</i> , 2012 , 19, 155-62	6	893
60	Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SARcoma treatment and Burden of Illness in North America and Europe (SABINE) study. <i>Annals of Oncology</i> , 2012 , 23, 2763-2770	10.3	54
59	Cost of disorders of the brain in Europe 2010. <i>European Neuropsychopharmacology</i> , 2011 , 21, 718-79	1.2	987
58	Costs of care in a mild-to-moderate Alzheimer clinical trial sample: key resources and their determinants. <i>Alzheimer's and Dementia</i> , 2011 , 7, 466-73	1.2	30

57	Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients. <i>Alzheimer's and Dementia</i> , 2011 , 7, 318-27	1.2	98
56	Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease. <i>International Psychogeriatrics</i> , 2011 , 23, 73-85	3.4	73
55	The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 825-32	3.9	128
54	Sarcoma. <i>Annals of Oncology</i> , 2010 , 21, viii408-viii416	10.3	4
53	Cross sectional observational study on the societal costs of Alzheimer's disease. <i>Current Alzheimer Research</i> , 2010 , 7, 358-67	3	72
52	Assessment of potential measures in models of progression in Alzheimer disease. <i>Neurology</i> , 2010 , 75, 1256-62	6.5	25
51	The worldwide societal costs of dementia: Estimates for 2009. <i>Alzheimer's and Dementia</i> , 2010 , 6, 98-103	1.2	296
50	Cost of illness and drivers of cost in atrial fibrillation in Sweden and Germany. <i>Applied Health Economics and Health Policy</i> , 2010 , 8, 317-25	3.4	13
49	Willingness-to-pay for reductions in care need: estimating the value of informal care in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2010 , 25, 622-32	3.9	22
48	Costs of dementia in Hungary. <i>Journal of Nutrition, Health and Aging</i> , 2010 , 14, 633-9	5.2	16
47	Differences in resource use and costs of dementia care between European countries: baseline data from the ICTUS study. <i>Journal of Nutrition, Health and Aging</i> , 2010 , 14, 648-54	5.2	64
46	The Resource Utilization in Dementia (RUD) instrument is valid for assessing informal care time in community-living patients with dementia. <i>Journal of Nutrition, Health and Aging</i> , 2010 , 14, 685-90	5.2	101
45	The cost of diagnosing dementia in a community setting. <i>International Journal of Geriatric Psychiatry</i> , 2010 , 25, 476-82	3.9	15
44	Methodological issues in primary prevention trials for neurodegenerative dementia. <i>Journal of Alzheimer's Disease</i> , 2009 , 16, 235-70	4.3	33
43	Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2009 , 24, 1072-8	3.9	11
42	Resource use and societal costs for Crohn's disease in Sweden. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 1882-90	4.5	25
41	Health-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: Gd-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany, Italy and Sweden. <i>European Radiology</i> , 2009 , 19 Suppl 3, S753-63	8	45
40	The cost of dementia in Europe: a review of the evidence, and methodological considerations. <i>Pharmacoeconomics</i> , 2009 , 27, 391-403	4.4	118

39	PMH56 A PATIENT PERSPECTIVE ON SIDE EFFECTS OF ANTIPSYCHOTIC THERAPY: THE TOOL INSTRUMENT. <i>Value in Health</i> , 2009 , 12, A361	3.3	5
38	PMH58 TOOL: MULTI-ATTRIBUTE UTILITY FUNCTION REFLECTING PATIENT EXPERIENCE OF SIDE EFFECTS TO ANTIPSYCHOTIC THERAPY. <i>Value in Health</i> , 2009 , 12, A361-A362	3.3	3
37	Community occupational therapy for older patients with dementia and their care givers: cost effectiveness study. <i>BMJ, The</i> , 2008 , 336, 134-8	5.9	189
36	Time use and costs of institutionalised elderly persons with or without dementia: results from the Nordanstig cohort in the Kungsholmen Project--a population based study in Sweden. <i>International Journal of Geriatric Psychiatry</i> , 2007 , 22, 639-48	3.9	38
35	Health utilities in mild cognitive impairment and dementia: a population study in Sweden. <i>International Journal of Geriatric Psychiatry</i> , 2007 , 22, 649-55	3.9	19
34	Patients with Lewy body dementia use more resources than those with Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2007 , 22, 713-9	3.9	73
33	Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. <i>Breast Cancer Research and Treatment</i> , 2007 , 102, 289-99	4.4	20
32	The ICTUS Study: A Prospective longitudinal observational study of 1,380 AD patients in Europe. Study design and baseline characteristics of the cohort. <i>Neuroepidemiology</i> , 2007 , 29, 29-38	5.4	45
31	Patients with dementia with lewy bodies have more impaired quality of life than patients with Alzheimer disease. <i>Alzheimer Disease and Associated Disorders</i> , 2007 , 21, 150-4	2.5	96
30	An estimate of the total worldwide societal costs of dementia in 2005. <i>Alzheimer's and Dementia</i> , 2007 , 3, 81-91	1.2	195
29	Determinants of costs of care for patients with Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2006 , 21, 449-59	3.9	169
28	An estimate of the worldwide prevalence and direct costs of dementia in 2003. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006 , 21, 175-81	2.6	208
27	Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. <i>Alzheimer Disease and Associated Disorders</i> , 2006 , 20, 49-55	2.5	109
26	Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. <i>Value in Health</i> , 2006 , 9, 193-8	3.3	92
25	Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. <i>American Journal of Geriatric Pharmacotherapy</i> , 2005 , 3, 77-86		33
24	Burden of illness of chronic low back pain in Sweden: a cross-sectional, retrospective study in primary care setting. <i>Spine</i> , 2005 , 30, 1777-85	3.3	137
23	Cost of dementia in Europe. <i>European Journal of Neurology</i> , 2005 , 12 Suppl 1, 50-3	6	35
22	Association between allergic rhinitis and hospital resource use among asthmatic children in Norway. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2005 , 60, 338-42	9.3	47

21	The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: results from the Study on COgnition and Prognosis in the Elderly. <i>Journal of Human Hypertension</i> , 2005 , 19, 569-76	2.6	13
20	The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). <i>British Journal of Rheumatology</i> , 2004 , 43, 1158-66		76
19	Cost of care for patients treated with lipid-lowering drugs. <i>Pharmacoeconomics</i> , 2004 , 22 Suppl 3, 25-35	4.4	19
18	Variations in pediatric asthma hospitalization rates and costs between and within Nordic countries. <i>Chest</i> , 2004 , 125, 1680-4	5.3	59
17	Costs of Dementia: A Review 2003 , 341-387		1
16	The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. <i>Rheumatology</i> , 2003 , 42, 326-35	3.9	131
15	Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease. <i>Pharmacoeconomics</i> , 2003 , 21, 1025-37	4.4	27
14	Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. <i>Pharmacoeconomics</i> , 2003 , 21, 305-14	4.4	94
13	Costs of Dementia: A Review 2002 , 335-381		4
12	Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2310-9		89
11	The potential economic consequences of cognitive improvement with losartan. <i>Blood Pressure</i> , 2002 , 11, 46-52	1.7	6
10	Pharmacoeconomic evaluation of calcipotriol (Daivonex/Dovonex) and UVB phototherapy in the treatment of psoriasis: a Markov model for The Netherlands. <i>Dermatology</i> , 2001 , 202, 38-43	4.4	13
9	Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis. <i>International Journal of Technology Assessment in Health Care</i> , 2000 , 16, 768-80	1.8	27
8	Economic consequences of the progression of rheumatoid arthritis in Sweden. <i>Arthritis and Rheumatism</i> , 1999 , 42, 347-56		139
7	Costs of Mini Mental State Examination-related cognitive impairment. <i>Pharmacoeconomics</i> , 1999 , 16, 409-16	4.4	52
6	The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. <i>Clinical Therapeutics</i> , 1999 , 21, 1230-40	3.5	83
5	Modeling cost of treatment with new topical treatments for glaucoma. Results from France and the United Kingdom. <i>International Journal of Technology Assessment in Health Care</i> , 1999 , 15, 207-19	1.8	31
4	Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. <i>Neurourology and Urodynamics</i> , 1998 , 17, 599-611	2.3	40

3	Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. <i>Graefers Archive for Clinical and Experimental Ophthalmology</i> , 1998 , 236, 811-21	3.8	46
2	The Art of Simulation 1989 , 235-245		
1	Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective?. <i>SSRN Electronic Journal</i> ,	1	18